Kbi-110 Jun 2026

KBI’s chemistry team screened >1.5 million compounds in a fluorescence‑polarization bromodomain binding assay. The top hit, a tricyclic hetero‑aryl scaffold (code‑named ), displayed sub‑micromolar affinity (K D ≈ 300 nM) but suffered from poor pharmacokinetics.

One of the biggest hurdles in immunotherapy is off-tumor toxicity—killing healthy cells by mistake. Because KBI-110 requires both targets to be present to work, it spares normal tissue. Early models suggest a much higher therapeutic window than first-generation bispecifics. KBI-110